by qfrsolutions | May 17, 2017 | News
Source: PR Newswire ALPHAEON Corporation (www.alphaeon.com) today announced that its wholly-owned subsidiary, Evolus Inc., submitted a Biologics License Application (BLA) for DWP-450, a Botulinum toxin Type A, to the U.S. Food and Drug Administration (FDA) seeking...
by qfrsolutions | Apr 25, 2017 | News
Source: FierceBiotech Sienna Biopharmaceuticals has raised $40 million to advance its pipeline of clinical-phase aesthetic and dermatology assets. The Series B round continues the rapid rise of Sienna, which has raised $86 million and bought Creabilis since it...
by qfrsolutions | Apr 19, 2017 | News
Source: FierceBiotech Cardinal Health will acquire Medtronic’s Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency units for $6.1 billion in cash in a deal slated to close in the quarter ending Sept. 30. The healthcare services company will gain...
by qfrsolutions | Apr 12, 2017 | News
Source: LinkedIn I’m sure you’ve been asked many times whether you’re an introvert or an extrovert. For some people, it’s an easy choice, but for most of us, it’s difficult to choose one way or the other. It’s hard to choose because the introvert/extrovert dichotomy...
by qfrsolutions | Mar 27, 2017 | News
Source: FierceBiotech Allergan and partner Paratek Pharmaceuticals have hit their primary endpoints in two key phase 3 acne trials for their investigational med sarecycline. The pair will now seek an FDA NDA in the second half of the year after the two...
by qfrsolutions | Mar 21, 2017 | News
Source: Cipher Pharmaceuticals Inc. (CPH.TO) (“Cipher” or “the Company”) announced today that veteran pharmaceutical industry executive Robert D. Tessarolo has been appointed President and Chief Executive Officer of Cipher, effective April 17 ,...
